In line with Canteen’s strategic plan, our policy and advocacy work seeks to build an integrated and holistic healthcare system that identifies, understands and responds to the unique needs of adolescents, young adults and families impacted by cancer.
Advocacy
Canteen's submission advocates for a stronger focus on AYA clinical trial eligibility as a key focus for the MRFF strategy.
Advocacy
Canteen strongly supports equity of access to clinical trials and novel therapeutics for the full spectrum of the adolescent and young adult population and therefore is strongly supportive of the TGA proposal in the adoption of these FDA guidelines.
Advocacy
Canteen would like the orphan drug program to consider the adolescent and young adult population as a unique group with a unique biology, different to that of peadiatric or adult populations.
Advocacy
Canteen applauds the establishment of the Medical Research Future Fund (MRFF) by the Australian Government and its flexibility to provide the opportunity to shape investment that will deliver improved health for Australians.
Advocacy
Canteen made five recommendations to the committee to ensure a commitment to equitable, timely and affordable access to new cancer drugs is prioritised for adolescents and young adults.
Find out more

Contact us for more information about our policy and advocacy work.